

**Memorial Sloan-Kettering Cancer Center and
Weill Medical College of Cornell University**
Curriculum vitae and Bibliography

Date of preparation: Thursday, July 17, 2014

A. GENERAL INFORMATION

- | | | |
|----|-------------------|---|
| 1. | Name | Ingo K. Mellinghoff, MD |
| 2. | Office address: | Memorial Sloan Kettering Cancer
1275 York Avenue, Box 20
New York, NY 10021 |
| | Office telephone: | 646-888-2766 |
| | Office fax: | 646-422-0856 |

B. EDUCATIONAL BACKGROUND

<i>Degree</i>	<i>Institution name and location</i>	<i>Year Awarded</i>
M.D.	Technische Universität München	1993

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Intern, Internal Medicine	Medizinische Poliklinik-Innenstadt, Ludwig- Maximilians-Universität München, Munich, Germany	01/94 - 05/95
Resident, Internal Medicine	University of California, Los Angeles, CA	06/95 - 06/98
Chief Resident, Internal Medicine	University of California, Los Angeles, CA	07/98 - 06/99
Fellow, Hematology/Oncology	University of California, Los Angeles, CA	07/99 - 06/02
Postdoctoral Fellow, Molecular Biology	Laboratory of Charles L. Sawyers, Howard Hughes Medical Institute, University of California, Los Angeles, CA	07/99 - 08/04

2. Academic positions (teaching and research)

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Assistant Professor, Department of Pharmacology	University of California, Los Angeles, CA	09/04 - 08/07
Assistant Member, Human Oncology and Pathogenesis Program	Memorial Sloan Kettering Cancer Center, New York, NY	09/07 - 08/12
Assistant Professor, Department of Pharmacology	Weill Cornell Medical College, New York, NY	09/07 - 08/12
Associate Member, Human Oncology and Pathogenesis Program	Memorial Sloan Kettering Cancer Center, New York, NY	09/12 - present
Associate Professor, Department of Pharmacology	Weill Cornell Medical College, New York, NY	09/12 - present
Vice Chair of Research, Department of Neurology	Memorial Sloan Kettering Cancer Center, New York, NY	04/13 - present
Evnin Family Chair in Neuro-Oncology	Memorial Sloan Kettering Cancer Center, New York, NY	12/13 - present

3. Hospital positions (e.g., attending physician)

<i>Title</i>	<i>Institution name, city and state</i>	<i>Dates</i>
Clinical Instructor, Department of Medicine	University of California, Los Angeles, CA	07/98 - 08/04
Member, Crump Institute for Molecular Imaging	University of California, Los Angeles, CA	09/04 - 08/07
Assistant Attending, Department of Neurology	Memorial Sloan Kettering Cancer Center, New York, NY	09/07 - 08/12

Associate Attending, Memorial Sloan Kettering Cancer Center, 09/12-present
Department of New York, NY
Neurology

4. Other Employment None

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

a. State	Number	Date of issue	Date of expiration
California	A061953	04-04-1997	04-30-2015
New York	247499	01-31-2008	01-31-2015

b. DEA number: BM5527405

c. NPI# 114030707

2. Board Certification

<i>Full Name of Board</i>	<i>Certificate #</i>	<i>Date (MM/DD/YY)</i>
American Board of Internal Medicine - Diplomate in Internal Medicine	#186294	11/04/1998
American Board of Internal Medicine - Diplomate in Medical Oncology	#186294	01/15/2003
American Board of Internal Medicine - Diplomate in Hematology	#186294	01/16/2004

3. Malpractice insurance

Do you have Malpractice insurance? Yes

Name of Provider: MSK Insurance US, Inc.

Premiums paid by: Memorial Sloan Kettering Cancer Center

E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies)

<i>Member/officer</i>	<i>Name of Organization</i>	<i>Dates</i>
Member	American Society of Clinical Oncology	2000 - present
Member	American Society of Hematology	2000 - present
Member	American College of Physicians - American Society of Internal Medicine	2001 - present
Member	American Association of Cancer Research	2006 - present
Member (Elected)	American Society of Clinical Investigators	2013 - present

F. HONORS AND AWARDS

<i>Name of award</i>	<i>Date awarded</i>
“Summa Cum Laude” High School Graduation (“Allgemeine Hochschulreife”), Bodenseegymnasium Lindau, Germany	1986
Bavarian Ministry of Education, Scholarship	1986
University of Massachusetts Medical School, Research Scholarship	1989 - 1990
American Society of Clinical Investigation, Trainee Travel Award	2001
American Society of Clinical Oncology (ASCO), Young Investigator	2003
William Guy Forbeck Scholar	2005
Sontag Foundation, Distinguished Scientist Award	2007
Doris Duke Foundation, Clinical Scientist Development Award	2008
Sidney Kimmel Foundation, Translational Scholar Award	2008
ASCO, Advanced Clinical Research Award in Glioma	2009
American Society of Clinical Investigation, Member	2013

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Diseases
Other Hospital Affiliations:	None
Other Institutional Affiliations:	Weill Cornell Medical College

H. EMPLOYMENT STATUS

Name of Employer(s): Memorial Sloan Kettering Cancer Center
Employment Status (*select from below*): Full-time

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT

1. Teaching/Mentoring

<u>University of California, Los Angeles</u>	
Morning Report, Internal Medicine Residents (daily)	1998 – 1999
Grand Rounds, UCLA Department of Medicine (weekly)	1998 – 1999
Case Studies in Pathophysiology of Disease, 2 nd medical students	1999 – 2003
Hematology Board Review, Internal Medicine Residents	2000 – 2001
Biological Imaging Course (M248),	2005 – 2007
Research Frontiers in Cellular and Molecular Pharmacology (M237)	2006 – 2007
Biomedical Physics Interdepartmental Graduate Program (260B)	2006 – 2007

Thesis Committees:

Andrew Yong-Moon Kwon, UCLA Department of Pharmacology	2004 – 2007
Shuping Qi, UCLA Department of Pharmacology	2005 – 2007
Alejandro Garcia, UCLA Department of Pharmacology	2005 – 2007
Seema Bhopale, UCLA Department of Pharmacology	2005 – 2007
Cathy Fang, UCLA Department of Pharmacology	2005 – 2007
Yinan (Fiona) Chen, UCLA Department of Pharmacology	2005 – 2007
Nam Vu, UCLA Interdepartmental Biomedical Physics Program	2006 – 2007

Memorial Sloan-Kettering and Weill Cornell

GSK Graduate School, Cancer Biology Core Course	2008 – present
Neurology Core Course 09-10	2009 – present
Weill Cornell Medical College, Molecular Pharmacology of Cancer	2009 – present
Molecular Imaging Seminar Series	2011 – present
Pharmacology II: Signal Transduction	2009 – present
Cancer Biology Course for Clinical Fellows	2010 – present

Thesis Committees:

Thesis Committee, Lindsay Saunders, GSK Graduate School	2010 – present
Thesis Committee, Michael Boice, Weill Cornell Graduate School	2010 – present
Thesis Committee, Poorvi Jayant Kaushik, CBM Program	2010 – present
ACE Committee, Ken Pitter, MDPhD Program	10-Nov-2010
Thesis Defense (Chair), Juliann Chmielecki, GSK Graduate School	14-Apr-2011
Thesis Committee, Nicholas Veomett, Weill Cornell Graduate School	2011– present
Master's Thesis Committee, Paige Yellen, CUNY	27-Sep- 2012
Thesis Defense (Chair), Ellen Hukkelhoven, GSK Graduate School	19-Dec-2012
Thesis Committee, Leili Ran, GSK Graduate School	2012 – present
Thesis Committe, Sunanya Gadal, Weill Cornell Graduate School	2012 – present
Thesis Committee, Amanda Moore, Weill Cornell Graduate School	2012 – present
Thesis Committee, Paul Jeng, Weill Cornell Graduate School	2013 – present

Laboratory members (previous and current):

- Postdoctoral Fellows: Milan Chheda, Owen Clark, Christian Grommes, Alexandra Miller, Phioanh Nghiemphu, Donna Nichol, Barbara Oldrini, Nicolaos Palaskas, Igor Vivanco
- Graduate Students: Daniel Rohle, Sara Kubek, Michael Kaufmann, Wan-Ying Hsieh
- Undergraduate Students: Sameer Aberwal, Jason Bradner, Michael Chen, Mira Nagarajan, Derrek Schartz, Aleksandra Stamper, Oriana Tang, Teli Hsueh, Nicholas Yanuzzi, Justin Yu

2. Clinical Care (duties, dates)

University of California, Los Angeles

Internal Medicine, Resident, UCLA Center for the Health Sciences 1995 – 1998

Hematology-Oncology, Fellow, UCLA CHS 1999 – 2002

Attending Physician, UCLA Center for the Health Sciences 1998 – 2007

Memorial Sloan-Kettering Cancer Center

Neurooncology, Attending Physician, Memorial Sloan-Kettering Cancer Center; weekly clinic for patients with primary brain tumors 2007 – present

3. Administrative duties, including committees, dates

University of California, Los Angeles

Medicine Service Mortality & Morbidity Committee, Member 1996 – 1998

Internal Medicine Residency Program Selection Committee, Member 1997 – 2007

Internal Medicine, Chief Resident, UCLA CHS 1998 – 1999

Medicine Service Mortality & Morbidity Committee, Co-Chair 1998 – 1999

Jonsson Comprehensive Cancer Center, Grant Review 2006 – 2007

Jonsson Comprehensive Cancer Center, Search Committee, Member 2006 – 2007

Department of Pharmacology Seminar Series (weekly), Host 2006 – 2007

Memorial Sloan-Kettering Cancer Center

Geoffrey Beene Cancer Research Retreat (annual), Co-Organizer 2008 - 2010

Brain Tumor Center, Seminar Series (biweekly), Host 2009 - 2011

Tri-Institutional MDPhD Program, Selection Committee 2009 – present

Brain Tumor Center, Grant Review 2013 – present

Society of MSK, Grant Review 2014 – present

Search Committee for Chair, Psychiatry and Behavioral Sciences 2014 – present

Technology Development Fund (TDF), Executive Committee 2014 – present

Center for Molecular Imaging and Nanotechnology, Grant Review 2014 – present

4. IRB Protocols

Biomarker Development

- IRB # 09-178, Development of Biomarkers to Evaluate Kinase Inhibitor Response in Glioma
Role: Principal Investigator
Status: open
- IRB # 10-131, Establishment of Primary CNS Lymphoma (PCNSL) Cell Lines From Patient Specimens
Role: Principal Investigator
Status: open

- IRB # 11-162, Ivy Foundation Early Phase Clinical Trials Consortium (Ivy CTC)
Virtual Tissue Bank for Malignant Glioma Patients
Role: Principal Investigator (MSKCC)
Status: open

Therapeutic Protocols

- IRB # 10-125, Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Role: Principal Investigator
Status: enrollment completed
- IRB # 12-002, A Phase II Study of BKM120 for Patients with Recurrent Glioblastoma and Activated PI3K Pathway
Role: Principal Investigator (MSKCC)
Status: enrollment completed
- IRB # 13-140, An Open-Label, Phase 2 Study Of Neratinib In Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR,HER2,HER3) Mutations Or EGFR Gene Amplification
Role: Co-Principal Investigator
Status: accruing
- IRB # 14-068, A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation
Role: Principal Investigator (MSKCC)
Status: accruing
- IRB # pending, Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma. A Protocol of the Adult Brain Tumor Consortium (ABTC)
Role: Study Co-Chair
Status: under review at MSK, approved by CTEP

5. Research

Department of Pharmacology, UCLA 2004 – 2007
Human Oncology and Pathogenesis Program, MSKCC 2007-present

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity Involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	5%	Yes	Yes
Clinical Care	20%	Yes	Yes
Administration	5%	No	No
Research	70%	Yes	Yes
	TOTAL: 100%		

J. RESEARCH SUPPORT

1. Completed Support

U. S. Department of Defense, Physician-Scientist Award 4/1/06-3/31/11
Total Amount: \$ 700,000 Annual Direct Cost: \$ 91,364
Title: Regulation of Androgen Receptor Function by ErbB Receptor Tyrosine Kinases
Role: Principal Investigator

Doris Duke Foundation, Clinical Scientist Development Award 8/1/08-7/31/11
Total Amount: \$405,000 Annual Direct Cost: \$125,000
Title: Determinants of Response to Targeted Therapy in Glioblastoma
Role: Principal Investigator

The Sontag Foundation, Distinguished Scientist Award 1/1/07-9/30/10
Total Amount: \$500,000 Annual Direct Cost: \$144,928
Title: Exploring the MET Signaling Axis in Glioma Biology and Drug Response
Role: Principal Investigator

American Society of Clinical Oncology 7/1/09-6/30/12
Total Amount: \$450,000 Annual Direct Cost: \$137,000
Title: Identification of Critical Signal Transduction Nodes during Glioma Progression
Role: Principal Investigator

Geoffrey Beene Cancer Research Center Grant (PI Mellinghoff) 8/1/10-7/31/12
Geoffrey Beene Cancer Research Center Annual Direct Cost: \$200,000
Total Amount: \$400,000
Title: Identification of aberrant signal transduction pathways in Primary CNS Lymphoma
Role: Principle Investigator

National Brain Tumor Society (PI: Mellinghoff) 9/1/11-8/31/12
Mary Catherine Calisto Systems Biology Initiative Annual Direct Cost: \$100,000
Total Amount: \$100,000
Title: A systems approach to develop PET imaging radiotracers for IDH1 mutant glioma
Role: Principal Investigator

2. Current Support

1R01NS080944-01 (PI: Mellinghoff) 11/01/12 – 10/31/17, 40%
National Institutes of Health Annual Direct Cost: \$ 229,843
Total Amount: \$378,936
Title: Molecular Mechanisms of IDH1-mediated Gliomagenesis
Role: Principal Investigator
The goal of this project is to advance our understanding of the molecular pathogenesis of IDH1-mutant human glioma.

James S. McDonnell Foundation Award (PI: Mellinghoff) 11/1/11-10/31/14, 30%
James S. McDonnell Foundation \$150,000/year
Total Amount: \$450,000
Title: Genotype Focused EGFR Targeting in Glioblastoma
Role: Principle Investigator
The goals of this project are to genetically explore single kinase EGFR dependence and its structural EGFR requirements in EGFR amplified/mutant GBM neurosphere lines and to develop pharmacological approaches to achieve “maximal” EGFR blockade in GBM.

Ivy Foundation Award (PI: Prados) 10/1/09-11/30/17
The Ben and Catherine Ivy Foundation Annual Direct Cost: \$ 132,642
Total Amount: \$245,489
Title: Ivy Foundation Early Phase Clinical Trials Consortium.
Role: Principal Investigator, MSKCC Projects
The goals of this project are to maximize output of clinical trials for GBM and optimize the identification of GBM patient subsets early on that are more likely to benefit from a therapeutic approach in clinical meaningful ways.

P50 CA086438-10 (PI: Larson) 9/16/11-6/30/16, 15%
National Institutes of Health \$75,000/year
Total Amount: \$375,000
Title: MSKCC Center for Molecular Imaging in Cancer (ICMIC)
Role: Project Leader – Research Project 4
The goals of this project are to use novel molecular imaging paradigms to address important clinical questions in oncology.

Physical Science-Oncology Center (U54) (PI: Michor, Holland) 10/1/09-9/30/14, 15%
1U54CA143798
National Cancer Institute \$135,904/yr direct
Total Amount: \$1,242,842
Title: Evolutionary Dynamics of Brain, Lung, and Hematopoietic Tumor Development
Role: Co- Leader-Project 1
The goal of this project is to develop a mathematical method to derive the sequence of genetic events during tumorigenesis using large crosssectional genomic datasets.

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

1. External Reviewer Service

a.) Journals

Cancer Research; Cancer Chemotherapy and Pharmacology; Cancer Discovery; Cancer Epidemiology, Biomarkers and Prevention; Cancer Letters; Cancer Science; Clinical Cancer Research; European Journal of Cancer; Experimental Cell Research; Genes, Chromosomes, and Cancer; International Journal of Cancer; Journal of Clinical Investigation; Journal of Neurooncology (Editorial Board), Journal of Nuclear Medicine; Molecular Cancer Therapeutics;

Nature; Nature Biotechnology; Nature Medicine; Nature Communications; Nature Reviews Clinical Oncology; Neurooncology (Editorial Board); New England Journal of Medicine; Neurology; Neuropathology and Applied Neurobiology; Oncogene; PLoS Medicine; PLoS ONE; Proceedings of the National Academy of Sciences, Science

b.) Grant Review

National Cancer Institute, Rapid Access to Intervention Development Program, Grant Reviewer (2006/2007)

Kentucky Science and Engineering Research Foundation (2005/2006)

Society of Neurooncology, Abstract Review for Annual Meeting (2007 – present), Scientific Program Committee (2011-present), Awards Committee (2012-present)

Burns & Allen Research Institute, Cedars Sinai Medical Center, Garber Award Review Panel (2007)

Children's Brain Tumor Foundation (CBTF)(2009), Grant Reviewer

Pediatric Low Grade Astrocytoma Foundation, Scientific Advisory Board, 2010-present

Cancer Research UK, Next Generation Sequencing Initiative, International Panel of Reviewers, 2011

NIH Scientific Review Group (ZRG1 BST-T 90 A), November 16, 2011 - November 18, 2011

The Luxembourg National Research Fund (FNR), Grant Reviewer for multi-annual research programme CORE 2012, 2013

Cancer Prevention and Research Institute of Texas (CPRIT), Dallas, TX, Translational & Clinical Review Committee, Grant Review Member, 2010-2012

NIH Scientific Review Group, Cancer Genetics Study Section (Adhoc Member), 2012-present

NIH Scientific Review Group, Fellowship: Oncology (Adhoc Member), 2012-present

NIH Scientific Review Group, Molecular Oncogenesis (Adhoc Member), 2013 – present

Conquer Cancer Foundation, Grants Selection Committee, 2013 - present

2. Invited Lectures

National Cancer Institute, Meeting of the Mouse Models of Human Cancers Consortium (MMHCC), Los Angeles, CA, January 8, 2004. Invited Speaker.

Academy of Molecular Imaging, Annual Meeting, Orlando, Florida, March 29, 2004. Invited Speaker.

American Association for Cancer Research (AACR), Annual Meeting, Anaheim, California, April 19th, 2005. Invited Speaker in Session “New Concepts in Organ Site Research – New Molecular Targets in Advanced Prostate Cancer.

Goldhirsh Foundation, Boston, MA, May 19, 2005, Invited Speaker.

National Cancer Institute, 13th SPORE Investigator Workshop, Washington, DC, July 11, 2005. Invited Speaker.

Association of Biomolecular Resource Facilities (ABRF), Annual Meeting, Long Beach, CA, February 12th, 2006, Invited Speaker in Session “Integrating Science, Tools, and Technologies with Systems Biology”

Harbor-UCLA Medical Center, Torrance, CA, May 2nd, 2006. Grand Rounds, Department of Medicine.

University of Southern California School of Pharmacy, Department of Molecular Pharmacology, Los Angeles, CA, October 27th, 2006. Seminar Speaker.

Dana-Farber Cancer Institute, Harvard University. Boston, MA, March 28th, 2007. Cancer Center Seminar Speaker.

American Association for Cancer Research (AACR), Annual Meeting. Los Angeles, April 16th, 2007. Co-Chair, Mini-Symposium: “Biomarkers of Clinical Outcomes”.

Georgia Institute of Technology and Emory University. The 2007 Frontiers of Cancer Nanotechnology Symposium. Callaway Gardens, Pine Mountain, GA. April 3rd, 2007. Keynote Speaker.

EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer, Brussels, Belgium, November 17th, 2007. Invited Speaker

AACR-ASH Joint Workshop on “PI3-Kinase: A Common Pathway for Hematologic Malignancies and Solid Tumors”, Lansdowne, Virginia, March 2-5, 2008. Invited Speaker.

American Association for Cancer Research (AACR), Annual Meeting, San Diego, California, April 15th, 2008. Co-Chair of Mini-Symposium on “Novel Genomic Approaches: Drugs, Targets, and Strategies”.

Association for Cancer Research (AACR) Conference on Targeting the PI3-Kinase Pathway in Cancer, Cambridge, MA, November 14, 2008. Invited Speaker.

Society of Neurooncology (SNO), Annual Meeting. Las Vegas, Nevada, November 20th, 2008. Invited Speaker during Education Day Session “Resistance to Targeted Molecular Therapies”.

Weill Cornell Medical College, Department of Pharmacology, New York, NY, December 9th, 2008. Seminar Speaker.

Ludwig Institute for Cancer Research, San Diego, California, January 22nd, 2009, Seminar Speaker.

Nemours Center for Childhood Cancer Research, Wilmington, DE, March 16th, 2009, Seminar Speaker.

University of North Carolina (UNC), Chapel Hill, North Carolina, March 17th, 2009. Cancer Center Seminar Speaker.

American Association for Cancer Research (AACR). Annual Meeting. Denver, CO, April 21th, 2009. Invited Speaker in Session “Translating Knowledge from the Cancer Genome Atlas (TCGA) to Understand and Control Cancer”.

European CanCer Organisation (ECCO) and European Society for Medical Oncology (ESMO). International Congress, Berlin, Germany, September 22, 2009. Invited Speaker in Session “Investigating novel targets and anti-angiogenic agents in brain tumors”.

American Society for Clinical Oncology (ASCO), Annual Meeting, Chicago, June 4th, 2010, Invited Speaker in Session entitled “Improving Clinical Trial Outcome in Neuro-Oncology”.

University of California, San Francisco (UCSF), San Francisco, CA, April 22, 2011. Cancer Center Seminar Speaker.

Society for Neuro-Oncology (SNO), Annual Meeting, Anaheim, California, November 19, 2011. Chair of Plenary Session.

New York Presbyterian Hospital – Weill Cornell Medical Center, New York, New York, March 7th 2012. Grand Rounds Department of Neurology and Neuroscience.

State University of New York (SUNY) Downstate Medical Center, Brooklyn, New York, March 9th 2012, Grand Rounds Department of Neurology.

American Society for Clinical Oncology (ASCO), Annual Meeting, Chicago, June 2nd 2012. Session Chair and Speaker “How and When Molecular Markers Should be Used in a Neurooncology Practice”.

James S. McDonnell Foundation, Symposium “Envisioning the Future Thru a Retrospective Lens: Lessons from 15 Years of JSMF Support for Brain Cancer Research”, MD Anderson, Houston, Texas, June 5-6, 2012, Invited Speaker.

19th International Brain Tumor Research and Therapy Conference, Niagara Falls, Canada, June 24th, 2012. Invited Speaker.

Ohio State University Wexner Medical Center, Columbus, Ohio, September 11th 2012, Invited Speaker, Brain Tumor Center Seminar.

National Brain Tumor Society, 2012 Summit, Boston, Massachusetts, October 10-11, 2012. Invited Speaker, “A systems approach to develop PET imaging radiotracers for IDH1 mutant glioma”.

Society for Neuro-Oncology (SNO), Annual Meeting, Washington DC, November 15, 2012. Education Day, Invited Speaker, “Growth Factor inhibitors: Rationale, Clinical Experience and Challenges”

American Association for Cancer Research and National Brain Tumor Society, Cancer Systems Biology Think Tank, Philadelphia, Pennsylvania, January 16-18, 2013. Session Co-Chair and Speaker, “Translational Challenges”.

MD Anderson Cancer Center, Houston, Texas. February 25-26, 2013. Invited Speaker, “Developing targeted therapies for glioma”.

American Association for Neurology, Annual Meeting, San Diego, California, March 20, 2013. Invited Speaker, Plenary Session.

Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, March 23, 2013. Invited Speaker, Neurology Grand Rounds.

Adult Brain Tumor Consortium Meeting, Chicago, Illinois, May 31st, 2013. Invited Speaker, “Development of Pharmacodynamic and Genomic Assays for Clinical Trials in Glioma”.

Aspen Cancer Conference, Aspen, CO, July 16th 2013, Invited Speaker, “Targeting Mutant Signaling Networks in Glioma”.

National Cancer Institute, Brain Malignancies Steering Committee Clinical Trials Planning Meeting, Chantilly, VA, September 19th 2013, Invited Speaker, “An Overview of Genomics of GBM and Therapeutic Opportunities”.

Memorial Sloan Kettering Cancer Center, New York, NY, March 14th 2014, Grand Rounds Office of Clinical Research.

American Association for Cancer Research (AACR), Annual Meeting, San Diego, California, April 6th, 2014. Invited Speaker, Major Symposia “IDH Mutations in Cancer”.

L. BIBLIOGRAPHY

1. RESEARCH ARTICLES

1. **Mellinghoff I.**, Daibata M., Humphreys R.E., Mulder C., Takada K., and Sairenji T. (1991). Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology, 185, 922-928.
2. Daibata D., **Mellinghoff I.**, Takagi S., Humphreys R.E., and Sairenji T. (1991). Effect of Genistein, a tyrosine kinase inhibitor, on latent EBV activation by cross-linkage of membrane IgG in Akata B cells. Journal of Immunology, 147, 292-297.
3. Marder V.J. and **Mellinghoff I.K.** Cocaine and Buerger Disease (2000). Is there a pathogenetic association? Archives of Internal Medicine, 160, 2057-2060.
4. Neshat MS, **Mellinghoff, I.K.**, Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. (2001). Enhanced sensitivity of PTEN deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A, 98, 10314-10319.
5. **Mellinghoff I.K.**, Winston D.J., Mukwaya G., and Schiller G.J. (2002) Scedosporium apiospermum brain abscesses treated with posaconazole. Clinical Infectious Diseases, 34, 1648-1650.
6. **Mellinghoff, I.K.**, Tran, C., and Sawyers, C.L. (2002). Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62, 5254-5259.
7. Gera, J.F., **Mellinghoff, I.K.**, Shi, Y., Rettig, M.B., Tran, C., Hsu, J.H., Sawyers, C.L., and Lichtenstein, A.K. (2004). AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem, 279, 2737-2746.
8. **Mellinghoff, I.K.**, Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., and Sawyers, C.L. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell, 6, 517-527.
9. Waldherr, C., **Mellinghoff, I.K.**, Tran, C., Halpern, B., Rozengurt, N., Safaei, A., Weber, W.A., Stout, D., Satyamurthy, N., Barrio, J., Phelps, M.E., Silverman, D.H., Sawyers, C.L., and Czernin, J. (2005). Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med, 46, 114-120.
10. **Mellinghoff, I.K.**, Wang, M., Vivanco, I., Haas-Kogan, D., Zhu, S., Dia, E., Lu, K., Yoshimoto, K., Huang, J., Chute, D., Riggs, B., Horvath, S., Liau, L., Cavenee, W., Rao, P., Beroukhi, R., Peck, T., Lee, J., Sellers, W., Stokoe, D., Prados, M., Cloughesy, T.F., Sawyers, C.L., Mischel, P.S. (2005). Molecular determinants of EGFR kinase inhibitor response in glioblastoma. The New England Journal of Medicine, 353, 2012-2024.

11. Thomas G.V., Tran C., **Mellinghoff I.K.**, Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. (2006). Hypoxia-inducible factor determines sensitivity to mTOR inhibitors in kidney cancer. Nature Medicine, 1, 122-127.
12. Xin L, Teitell M.A, Lawson D.A., Kwon A., **Mellinghoff I.K.**, and Witte O.N. (2006). Progression of prostate cancer by synergy of Akt with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A, 103, 7789-7794.
13. Beroukhim R., Lin M., Park Y., Hao K., Zhao X., Garraway L.A., Fox E.A., Hochberg E.P., **Mellinghoff I.K.**, Hofer M.D., Descoteaux A., Rubin M.A., Meyerson M., Wong W.H., Sellers W.R., and Li C. (2006). Inferring loss-of-heterozygosity from unpaired tumors using high-density SNP-Arrays. PLoS Comput Biol, 2(5); e41.
14. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackelford G.M., Cavenee W., **Mellinghoff I.K.**, Cloughesy T., Sawyers C.L., and Mischel P.S. (2006). Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res, 66(16): 7864-7869.
15. Lee J.C., Vivanco I., Beroukhim R., Huang J.H.Y., Feng W.L., DeBiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., Xu Q., Greulich H., Thomas R., Paez G., Peck T., Linhart D.J., Glatt K.A., Getz G., Onofrio R., Ziaugra L., Levine R.L., Gabriel S., Kawaguchi T., O'Neill K., Khan H., Liao L.M., Nelson S., Rao P.N., Mischel P., Pieper R., Cloughesy T., Leahy D.J., Sellers W.R., Sawyers C.L., Meyerson M., and **Mellinghoff I.K.** (2006). EGFR activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Medicine, 12 (3): e485.
16. Thomas R.K., Baker A.C., DeBiasi R., Winckler W., LaFramboise T., Lin W., Wang M., Feng W., Zander T., MacConaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majumdar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A.F., Minna J., Armstrong S., **Mellinghoff I.K.**, Hodi F., Dranoff G., Mischel P., Cloughesy T., Nelson S., Liao L., Mertz K., Rubin M., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., Garraway L.A. (2007). High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 39 (3): 1-5.
17. Carlson M.R., Pope W.B., Horvath S., Braunstein J.G., Nghiemphu P., Tso C.L., **Mellinghoff I.K.**, Lai A., Liao L.M., Mischel P.S., Dong J., Nelson S.F., Cloughesy T.F. (2007). Relationship between Survival and Edema in Malignant Gliomas: role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. Clin Cancer Res, 13 (9): 2592-2598.
18. Vivanco I., Palaskas N., Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, **Mellinghoff I.K.**, Davis RJ, Wu H, Sawyers CL. (2007). Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell, 11: 555-569.

19. Beroukhim R, Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., Vivanco I., Lee J.C., Huang JH, Alexander S, Du J., Kau T., Thomas R.K., Shah K., Soto H., Perner S., Prensner J., Debiase R.M., Demichelis F., Hatton C., Rubin M.A., Garraway L.A., Stan F. Nelson S.F., Liao L., Mischel P.S., Cloughesy T.F., Meyerson M., Golub T.A., Lander E.S. #, **Mellinghoff I.K.** #, and W.R. Sellers # (2007). Genome-wide analysis of chromosomal aberrations in glioma. Proc Natl Acad Sci U S A, 104 (50): 20007-20012. # **corresponding authors**
20. Yoshimoto K., Dang J., Zhu S., Nathanson D., Huang T., Dumont R., Seligson D.B., Yong W.H., Xiong Z., Rao N., Winther H., Chakravarti A., Bigner D.D., **Mellinghoff I.K.**, Horvath S., Cavenee W.K., Cloughesy T.F., Mischel P.S. (2008). Detection of EGFRvIII in routinely processed glioblastoma clinical samples. Clinical Cancer Research, 14(2): 488-493.
21. Cloughesy T.F. #, Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liao L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koletto M., Trent J., Horvath S., Mischel P.S. #, **Mellinghoff I.K.** #, and C.L. Sawyers # (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Medicine, 5(1): e8. # **corresponding authors**
22. Du J., Bernasconi P., Clauser K.R., Mani D.R., Finn S.P., Beroukhim R., Burns M., Julian B., Peng X.P., Hieronymus H., Maglathlin R.L., Lewis T.A., Liao L.M., Nghiemphu P., **Mellinghoff I.K.**, Louis D., Loda M., Carr S.A., Kung A.L., and T.R. Golub (2009). Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as potential target for glioblastoma therapy. Nature Biotechnology, 27(1):77-83.
23. Veeriah S., Brennan C., Meng S., Singh B., Fagin J.A., Solit D.B., Paty P.B., Rohle D., Vivanco i., Chmielecki J., Pao W., Ladanyi M., Gerald W.L., Liao L., Cloughesy T.C., Mischel P.S., Sander C., Taylor B., Schultz N., Major J., Heguy A., **Mellinghoff I.K.**, and T.A. Chan (2009). The protein tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A, 106(23): 9435-40.
24. Meng S., Arbit T., Veeriah S., **Mellinghoff I.K.**, Fang F., Vivanco I., Rohle D., Chan T.A. (2009). 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle, 8 (14): 2238-46.
25. McGillicuddy L.T., Fromm J.A., Kubek S., Beroukhim R, De Raedt T., Hollstein P.E., Johnson B.W., Nghiemphu P., Liao L., Cloughesy T., Mischel T., Stemmer-Rachamimov A.O., Sawyers C., Brennan C., Messiaen L., **Mellinghoff I.K.**, and K. Cichowski (2009). Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell, 7; 16(1): 44-54.
26. Regales L., Gong Y., Shen R., deStanchina E., Vivanco I., Goel A., Koutcher J.A., Spassova M., Querfelli O., **Mellinghoff I.K.**, Zakowski M., Politi K.A., and W. Pao (2009). Dual targeting of EGFR can overcome acquired resistance to EGFR inhibitors in EGFR mutant lung cancer. Journal of Clinical Investigation, 119(10): 3000-10.

27. Gregorian C., Nakashima, J., Dry, S.M., Nghiemphu, P.L., Smith, K.B., Ao, Y., Dang, J., Lawson, G., **Mellinghoff I.K.**, Mischel, P.S., Phelps, M., Parada L., Liu X., Sofroniew, M.V., Eilber F.C., and Wu, H. (2009) PTEN Dosage Is Essential for Neurofibroma Development and Malignant Transformation. Proc Natl Acad Sci U S A, 106 (46):19479-84.
28. Guo D., Prins R.M., Dang J., Kuga D., Iwanami A., Soto H., Lin K.Y., Huang T.T., Akhavan D., Hock M.B., Zhu S. Kofman A.A., Bensinger S.J., Yong W.H., Vinters H.V., Horvath S., Watson A.D., Kuhn J.G., Robins H.I., Mehta M.P., Wen P.Y., DeAngelis L.M., Prados M.D., **Mellinghoff I.K.**, Cloughesy T.F., Mischel P.S. (2009). EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling, 2 (101): ra82.
29. Peng L., Wu, T., Tchieu, J.H., Feng, J., Brown, H.J., Feng, J., Li, X., Qi, J., Deng, H., Vivanco, I., **Mellinghoff, I.K.**, Jamieson, C., Sun, R. (2010) The Inhibition of PI3K-Akt Pathway Enhances Gamma-2 Herpesvirus Lytic Replication and Facilitates Reactivation from Latency. Journal of General Virology, 91 (Pt 2):463-9.
30. Veeriah, S., Taylor, B. S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Schultz, N., Janakiraman, M., Pao, W., Ladanyi, M., Sander, C., Heguy, A., Holland, E., Paty, P. B., **Mellinghoff, I.K.**, Solit, D.B., and Chan, T.A (2010). Somatic Mutations of the familial Parkinson's Disease gene PARK2 in glioblastoma and other human malignancies. Nature Genetics, 42(1):77-82.
31. Vivanco, I., Rohle, D., Versele, M., Iwanami, A., Kuga, D., Oldrini, B., Dang, J., Kubek, S., Palaskas, N., Hsueh, T., Evans, M., Mulholland, D., Wolle, D., Rajasekaran, S., Rajasekaran, A., Liao, L.M., Tim F. Cloughesy, T.F., Dikic, I., Brennan, C., Wu, H., Mischel, P.S., Perera T., and **Mellinghoff I.K.** (2010) The Phosphatase and Tensin homolog regulates Epidermal Growth Factor Receptor Inhibitor Response by Targeting EGFR for Degradation. Proc Natl Acad Sci U S A, 107(14):6459-64.
32. Stephan-Otto Attolini, C., Cheng Y.-K., Beroukhim, R., Gad Getz, G., Abdel-Wahab, O., Levine, R.L., **Mellinghoff, I.K.**, and Michor F. (2010). A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A, 107(41):17604-9.
33. Palaskas N., Larson S.M., Schultz N., Komisopoulou E., Wong J., Rohle D., Campos C., Yannuzzi N., Osborne J.R., Linkov I., Kastenhuber E.W., Taschereau R., Plaisier S.B., Tran C., Heguy A., Wu H., Sander C., Phelps M.E., Brennan C., Port E., Huse J.T., Graeber T.G., **Mellinghoff I.K.** (2011). 18F-fluorodeoxy-glucose Positron Emission Tomography (18-FDG-PET) Marks Basal-Like Human Breast Cancer with MYC Overexpression. Cancer Research, 71(15): 5164-5174.
34. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, **Mellinghoff IK**, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS (2011). An LXR Agonist

Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. Cancer Discovery. 2011 Oct;1(5):442-456. Epub 2011 Sep 15.

35. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kasthuber ER, Banuchi VE, Singh B, Heguy A, Viale A, **Mellinghoff IK**, Huse J, Ganly I, Chan TA (2011). Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011 Nov 7.

36. Cheng Y.-K., Beroukhi R., Levine R.L., **Mellinghoff I.K.**, Holland E.C., Michor F (2012). A computational methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol, Jan; 8(1):e1002337. PMID: 22241976

37. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C., Khanin R., Figueroa M.E., Melnick A., Wellen K.E., O'Rourke D.M., Berger S.L., Chan T.A., Levine R.L., **Mellinghoff I.K.**, Thompson C.B. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Feb 15; 483 (7390):474-8. PMID: 22343901.

38. Turcan S., Rohle D, Goenka A., Walsh L., Fang F., Yilmaz E., Campos C., Fabius A.M., Lu C., Ward P.S., Thompson C.B., Kaufman A., Heguy A., Viale A., Morris L.G.T., Huse J.T., **Mellinghoff I.K.** #, T.A. Chan #. # **corresponding authors**. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. Feb 15; 483(7390):479-83. PMID: 22343889.

39. Gorovets D, Kannan K, Shen R, Kasthuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, **Mellinghoff IK**, Chan TA, Huse JT. (2012) IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. Clin Cancer Res. May 1; 18(9):2490-501.PMID: 22415316

40. Vivanco I, Robins H.I., Rohle D., Campos C., Grommes C., Nghiemphu P., Kubek S., Oldrini B., Chheda M.G., Yannuzzi N., Tao H., Zhu S., Iwanami A., Kuga D., Dang J. , Pedraza A., Brennan C., Heguy A., Liao L.M., Lieberman F., Yung W.K., Gilbert M.R., Reardon D., Drappatz J., Wen P.Y., Lamborn K., Chang S.M., Prados M.D., Fine H.A., Horvath S., Wu N., Lassman A.B., DeAngelis L.M., Yong W.H., Kuhn J.G., Mischel P.S., Mehta M.P., Cloughesy, T.F., and **Mellinghoff I.K.** (2012) Differential Sensitivity of Glioma- versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors. Cancer Discovery. May; 2(5):458-471.

41. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mitra E, Pitter K, Huang R, Campos C, Habte F, Sinclair R, Brennan CW, **Mellinghoff IK**, Holland EC, Gambhir SS (2012). A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine. Apr 15; 18(5):829-34. PMID: 22504484.

42. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, **Mellinghoff IK**, Mischel PS and Graeber TG. (2012) Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Molecular Systems Biology 8:589. PMID: 22735335.

43. Huang R, Vider J, Kovar JL, Olive DM, **Mellinghoff IK**, Mayer-Kuckuk P, Kircher MF and Blasberg RG. (2012) Integrin alpha v beta 3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clinical Cancer Research 18(20):5731-40. PMID: 22914772.
44. Liu Y, Liu F, Yu H, Zhao X, Sashida G, Deblasio A, Harr M, She QB, Chen Z, Lin HK, Di Giandomenico S, Elf SE, Yang Y, Miyata Y, Huang G, Menendez S, **Mellinghoff IK**, Rosen N, Pandolfi PP, Hedvat CV and Nimer SD. (2012) Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Science Signaling 5(247):ra77. PMID: 23092893.
45. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, **Mellinghoff IK**, Sawyers CL and Lewis JS. (2013) Imaging Tumor Burden in the Brain with 89Zr-Transferrin. Journal of Nuclear Medicine 54(1): 90-5. PMID: 23236019.
46. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF and **Mellinghoff IK** (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncology 15(2):242-50. PMID: 23243055.
47. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan S, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly I, Liao L, Cloughesy TC, Mischel PS, **Mellinghoff IK**, Chan TA. (2013) Nature Genetics 45(3): 253-61. PMID: 23354438.
48. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, **Mellinghoff IK**. (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (6132): 626-30. PMID: 23558169.
49. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, **Mellinghoff IK**, Cavenee WK, Shaw RJ, Mischel PS. (2013) mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc. Cell Metabolism 18 (5): 726-39. PMID: 24140020.
50. Chudnovsky Y, Kim D, Zheng S, Whyte WA, Bansal M, Bray MA, Gopal S, Theisen MA, Bilodeau S, Thiru P, Mitalipova M, Muffat J, Woolard K, Lee J, Nishimura R, Sakata N, Fine HA, Carpenter AE, Silver SJ, Verhaak R, Califano A, Young RA, Ligon KL, **Mellinghoff IK**, Root DE, Sabatini DM, Hahn WC, Chheda MG. (2014) ZFHx4 is a master regulator of NuRD core member CHD4 and regulates the glioblastoma tumor initiating cell state. Cell Reports 6 (2): 313-24. PMID: 24440720.

2. EDITORIALS AND INVITED REVIEWS

1. **Mellinghoff, I.** and Sawyers, C.L. (2000) Kinase Inhibitor Therapy in Cancer. PPO Updates, Principles & Practice of Oncology, Vincent T. Devita, Jr., Samuel Hellman, Steven A. Rosenberg (Eds). 5th Edition. Lippincott Williams & Wilkins 14(12):1-11.
2. **Mellinghoff I.K.**, Sawyers C.L. (2002). The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics, 3(5):603-623.
3. **Mellinghoff, I.K.**, and Sawyers, C.L. (2004). TORward AKTually useful mouse models. Nature Medicine 10, 579-580.
4. **Mellinghoff, I.K.** (2006) Novel Approaches to Androgen Receptor Blockade. In: Prostate Cancer: Translational and Emerging Therapies. N. A. Dawson and W. K. Kelly (editors), Taylor and Francis Publishing Group.
5. **Mellinghoff, I.K.**, Cloughesy T.F., Mischel, P.M. (2007). Molecular Pathways: PTEN-mediated resistance to EGFR kinase inhibitors. Clinical Cancer Research, 15: 378-81.
6. **Mellinghoff I.K.** (2007) Why Do Cancer Cells Become "Addicted" to Oncogenic Epidermal Growth Factor Receptor? PLoS Medicine, 4 (10), e321.
7. Beroukhim R, Getz G., and **Mellinghoff I.K.** (2009) Genomic Identification of Significant Targets in Cancer (GISTIC): Methodology and Application to Glioma and Other Cancers. In: CNS Cancer. Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches. E. Van Meir (eds). Springer.
8. Vivanco I., **Mellinghoff I.K.** (2010). Epidermal growth factor inhibitors in oncology. Current Opinions in Oncology. 22(6):573-8. PMID: 20739887
9. Solit D.B and **Mellinghoff I.K.** (2010). Tracing cancer networks with phosphoproteomics. Nature Biotechnology, 28(10): 1028-9. PMID: 20944590
10. **Mellinghoff I.K.**, Lassman A.B., and P.Y. Wen (2011). Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia, 59(8):1205-12. PMID: 21351155
11. DeAngelis L.M., **Mellinghoff I.K.** (2011). Virchow 2011 or How to ID(h) Human Glioblastoma. Journal of Clinical Oncology, 29(34):4473-4. PMID: 22025161.
12. **Mellinghoff I.K.**, N. Schultz, P.S. Mischel, and T.F. Cloughesy (2011). Will Kinase Inhibitors make it as Glioblastoma Drugs? Curr Top Microbiol Immunol. 2011 Oct 21. PMID: 22015553. **in: Mellinghoff IK** and Sawyers CL (eds). Therapeutic Kinase Inhibitors, Springer, ISBN 978-3-642-28295-9.